CN1251696C - Medicine for treating tuberdulosis and lung disease and its preparing method - Google Patents
Medicine for treating tuberdulosis and lung disease and its preparing method Download PDFInfo
- Publication number
- CN1251696C CN1251696C CN 03117534 CN03117534A CN1251696C CN 1251696 C CN1251696 C CN 1251696C CN 03117534 CN03117534 CN 03117534 CN 03117534 A CN03117534 A CN 03117534A CN 1251696 C CN1251696 C CN 1251696C
- Authority
- CN
- China
- Prior art keywords
- medicine
- tuberculosis
- radix
- caulis
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicine for curing tuberculosis and a preparation method thereof. In the present invention, forrest silkvine root, or forrest silkvine root, milkvetch root and ophiopogon root are used as raw materials. According the preparation method for the medicine, effective components of the medicines are extracted, and are prepared into capsules or tablets. The medicine of the present invention has unique formulation, and unique curative effect on both medicine resistant patients with tuberculosis and non medicine resistant patients with tuberculosis due to double functions of resisting tuberculosis for sterilization and restoring vital energy for bacteriostasis. Patients who continuously take the medicine can not generate medicine resistance. The clinical curative effect is higher than that of other medicines, and the medicine has obvious curative effect. The medicine of the present invention not only comprises components with strong functions of relieving, sterilizing and restrainting bacteria, but also comprises effective components, such as cardiac glycoside, astragaloside IV, astragalus polysaccharide, asparagus polysaccharide, more than 10 amino acids, a plurality of beneficial microelements, etc. which enhance the immunity and disease resistance of the human body. The components all have favorable protective functions of secondary pathological changes-cor pulmonale of tuberculosis.
Description
Technical field
The present invention relates to a kind of smelting and treat the medicine of tuberculosis, pneumonopathy, be the Chinese patent medicine of feedstock production specifically with the Chinese herbal medicine, be mainly used in treatment pulmonary tuberculosis (and other tuberculosis), pneumonia, pulmonary edema, acute/chronic bronchitis the invention still further relates to the preparation method of this medicine.
Background technology
Tuberculosis is a kind of ancient global chronic infection disease, be the disease kind that the strong utmost point refractory of a kind of infectiousness is healed the forties in 19th century in the past, from streptomycin, isoniazid, after tuberculosis specific drugs such as rifampicin come out, cure rate lungy reaches more than 95%, and case fatality rate drops to below the control line.Since the eighties, tuberculosis is staged a comeback in the world, epidemic situation is gone up, its main cause is: be subjected to the influence of the biological variation of mycobacterium tuberculosis strain, antitubercular agent isoniazid efficiently, streptomycin, drug resistance has appearred in chemotherapeutics such as rifampicin, has occurred heavy many toxicities behind the continuous use, the patient or the drug-fast patient of Secondary cases (resistant tuberculosis people reaches about 50%) that infected by the mycobacterium tuberculosis strain of anti-the multiple medicines, reach the several years course of treatment, ten several years, the medicine is expensive, and cure rate is low, case fatality rate height, tuberculosis become the first killer and the maximum cause of death in all infectious disease again.Nineteen ninety-five, the world health group gave a warning to countries in the world, and the appearance of Resistant strain might make tuberculosis become incurable disease once more.World tuberculosis worldwide federation is at modern times epidemic situation characteristics lungy, proposing antiphthisic new drug research guide is: stronger sterilization, bacteriostasis are arranged and resist chemical sproof effect, also the course of treatment must be shortened, production cost is low, moderate cost, the patient of developing country backward in economy also can accept.
In the ill crowd of tuberculosis, pulmonary tuberculosis patient accounts for about 85%.Pulmonary tuberculosis with cough, hemoptysis, low grade fever, night sweat, poor appetite, become thin, pain uncomfortable in chest is primary symptom, pathological changes such as the inflammation, edema of companion's lungs, hemorrhage, empty, fibrosis calcification, pathological changes such as secondary insufficiency of pulmonary function, pulmonary heart disease.Treatment lungy to be to kill intravital tubercule bacillus, need improve patient's tuberculosis poisoning symptom (heating, night sweat, poor appetite, become thin etc.) simultaneously, and the enhance immunity resistance against diseases promotes the reparation of pathological tissues.Therefore the immune disease-resistance ability of bactericidal and enhancing body is treatment two important aspects lungy.
Treatment lungy, carry out with isoniazid countries in the world at present, rifampicin is main, the Western medicine chemotherapy regimen of 2-5 kind antitubercular agent coupling, but isoniazid, rifampicin exists independent medication, perhaps drug combination is after March, drug resistance rises month by month, the bactericidal effect obviously reduces, neurotoxicity and liver can appear in continuous use, injury of kidney etc., as take for a long time isoniazid can secondary neuritis slightly not, the clothes rifampicin class antitubercular agent patient yellow of urinating, continuous use can cause hepatitis due to medicine, pathological changes such as renal failure need and protect the liver, the drug combination of kidney, strepto-have very strong acoustic nerve toxicity, lifelong deafness can take place in continuous use, the side reaction that auditory dysesthesia etc. are serious, these toxicities and chemical sproof generation have a strong impact on patient's medication toleration, have to use instead the three-way antituberculosis drugs treat in two wires, existing Shang Shi two wires, three-way tuberculosis chemotherapeutics is lower than said medicine as the bactericidal effect of ethambutol etc., exists the course of treatment long, the medicine is expensive, the low deficiency that waits of cure rate.
Some Chinese patent drugs of present new listing, as tuberculosis granule, stilbene shellfish capsule etc., toxic and side effects is very little, majority has the effect of enhance immunity resistance against diseases preferably, but because the bactericidal effect is not obvious, only treat medicine, do not find the pure middle preparation of the close plans of chemotherapy medicine such as bactericidal effect and rifampicin class, isoniazid at present as yet as antiphthisic complementary smelting.
Summary of the invention
The object of the present invention is to provide a kind of obvious sterilization bacteriostasis that has, the enhance immunity premunition is to drug resistance tulase patient-comprise that resistant tuberculosis people and non-resistant tuberculosis have definite curative effect, the Chinese herbal and crude drugs preparations that toxicity is minimum per capita.
Another object of the present invention provides the preparation method of this antitubercular agent.
Solution of the present invention is from the secret recipe handed down in the family of treatment rheumatic ostalgia among the people, (this product is Asclepiadaceae plant Caulis et Radix Periplocae Forrestii periplocaforrestii Schltr to filter out the Chinese herbal medicine Caulis et Radix Periplocae Forrestii with tangible anti-consumptive disease bactericidal action, and the dry stem of blue or green mabi periploca calophylla (Wight) Falc. and root, leaf), also can replace Caulis et Radix Periplocae Forrestii with spending more blue or green mabi or P. sepium Bunge, the active princlple that extracts this medicine is used for the treatment of tuberculosis.Caulis et Radix Periplocae Forrestii medical material involved in the present invention, present known function is a wind-damp dispelling, invigorates blood circulation, antiinflammatory, cure mainly rheumatic arthritis, traumatic injury, stomatitis etc., normal and other medical material is formed antiheumatic compound preparation, chases after the deep capsule of wind as Heiguteng exract, Caulis et Radix Periplocae Forrestii rheumatic bone-setting ball etc.It is raw material that the present invention has disclosed with the Caulis et Radix Periplocae Forrestii, or to select with the Caulis et Radix Periplocae Forrestii be the medicament that primary raw material is prepared from, the special produce effects in treatment tuberculosis.
Solution of the present invention is based on the traditional Chinese medical science to pathogenesis understanding lungy and Therapeutic Principle, utilizes modern pharmacology, toxicologic study method, and having filtered out the germ-resistant Chinese herbal medicine Caulis et Radix Periplocae Forrestii of tangible anti-consumptive disease is raw material; Can also select Caulis et Radix Periplocae Forrestii is primary raw material (accounting for more than 60% of total raw material), the medicine that is aided with YIN nourishing and QI supplementing, enhancing human body immunity is (as the Radix Astragali, Radix Ophiopogonis, Bulbus Fritillariae Uninbracteatae, Pseudobulbus Bletillae (Rhizoma Bletillae) ...) composition of raw materials, extract its effective active component, to pulmonary tuberculosis and other tuberculosis, anti-consumptive disease sterilization is arranged and set upright the bacteriostatic dual function, simultaneously to treating poisoning symptom lungy (cough, hemoptysis, fever due to yin deficiency, night sweat, become thin etc.), the detoxifcation cough-relieving is arranged, the effect that tonify deficiency is set upright.The bactericidal antiphlogistic of this medicine, tonify deficiency centralizing function simultaneously to other pulmonary disease, also have definite curative effect as pneumonia, pulmonary edema, acute/chronic bronchitis, pleuritis etc.
Medicine of the present invention is made by following component: (consumption is weight percentage)
1, Caulis et Radix Periplocae Forrestii 100%
Its preparation method is:
Get Caulis et Radix Periplocae Forrestii, 50～75% soak with ethanol that add up 3～6 times of spice amounts are after 3～7 days, and filter is pure liquid to the greatest extent, reclaims ethanol, and medicinal liquid is standby; Medicinal residues decoct three times again, add for the first time the water boil 2～3 hours of 5～8 times of amounts, and second and third time respectively adds the water of 3～4 times of amounts, respectively boiled 1～2 hour, and merged three times filtrate, filter while hot, leave standstill clarification 8～10 hours, get supernatant and filter, filtrate and above-mentioned medicinal liquid, separation impurity removing technology purification routinely with filter press, purified medicinal liquid is condensed into rare thick paste (proportion 1.05～1.15,60 ℃ of heat surveys) spray drying is made fine silt, and the pelletizing press sheet or the branch of granulating are encapsulated, and packing promptly.
2, the each component consumption of compositing formula:
1%～20% Radix Ophiopogonis 0%～20% of the Caulis et Radix Periplocae Forrestii 60%-99% Radix Astragali
Preparation medicine of the present invention the scope of formula optimization weight proportion be:
5%～15% Radix Ophiopogonis 5%～15% of the Caulis et Radix Periplocae Forrestii 70%-90% Radix Astragali
Above-described treatment tuberculosis also can add the medicine of cough-relieving tonifying the lung such as Bulbus Fritillariae Uninbracteatae.
Above-mentioned each component is made medicine production method of the present invention is:
1, with above-mentioned each component by following requirement evaluation, remove impurity:
(1), Heiguteng exract.The finger Asclepiadaceae is shouldered the Caulis et Radix Periplocae Forrestii of platymiscium, blue or green mabi, spends more blue or green mabi.
(2), meet the Radix Astragali, Radix Ophiopogonis every regulation under the Pharmacopoeia of the People's Republic of China Radix Astragali, the Radix Ophiopogonis item.
2, the medicine production method is with the method for above-mentioned three kinds of components by boiling water extraction method or alcohol extraction water boiling and extraction, extracts the active princlple in three kinds of components, produces medicines such as capsule, tablet, granule after the purification.
That is: with above-mentioned three kinds of components, decoct with water three times, add 6～8 times of water yields for the first time, soak after 6～8 hours, heated and boiled 120～180 minutes, for the second time add 3～4 times of water yield water boils 100～120 minutes, clarified 8～10 hours, add 2 times of water boils 90～120 minutes for the third time, merge three times medicinal liquid, filter while hot, leave standstill clarification 8～10 hours, get the supernatant mechanism filter-pressing, filtrate is condensed into rare thick paste (proportion 1.05～1.35, heat is surveyed 60 ℃), spray drying is made fine silt, granulates, check, capsule charge, packing, promptly.
An important feature of the present invention is: according to modern times pathology lungy, medical knowledge characteristics, abide by the anti-consumptive disease sterilization of the traditional Chinese medical science, set upright bacteriostatic rule of treatment scientific formula, anti-consumptive disease sterilization, tonify deficiency bacteriostatic dual-use function that we are unique, Here it is this medicine is to many resistant tuberculosis people, non-resistant tuberculosis people, unique curative effect is all arranged, continuous use does not produce drug resistance, and clinical efficacy is higher than the reason of other class medicine.
Another important feature of the present invention is: medicine of the present invention is except containing the component with intensive anti-inflammation and sterilization, bacteriostasis; still contain the active princlple that strengthens the human immunity resistance against diseases; as cardiac glycoside, astragaloside, astragalus polysaccharides; Radix Ophiopogonis polysaccharide, ten several amino acids, multiple beneficial trace element etc., these components are to pulmonary tuberculosis and Secondary cases pathological changes--pulmonary heart disease has good protective effect.
For showing medicine of the present invention to therapeutic effect lungy, medicine of the present invention carries out pharmacodynamics, toxicology test research, and the result is as follows:
1, in vitro tests studies show that: adopt the absolute concentration method, and modified Russell medium test tube cultivation results, this medicine is 50-150ug to the H37RV minimum inhibitory concentration.The extracorporeal bacteria inhibitor test result of study is higher than existing similar medium-height grass medicine.
2, the intravital tuberculosis experimentation of medicine of the present invention:. set up the Cavia porcellus tuberculosis model of H37RV strain infection, with this medicine is experimental group, set up isoniazid, isoniazid ten rifampicin, the positive control drug group of ethambutol, set up 8 treated animals such as tuberculosis model blank group and normal control group simultaneously, 8 every group; Body weight with laboratory animal, the naked eyes pathological changes is observed index, the organ weights index is for detecting index, carry out the equivalent comparative study of tuberculosis effect, experiment conclusion is: the height of medicine of the present invention, in, low dose group is equivalent to 10 times of clinical medicine dose, 5 times, 2.5 doubly) tangible tuberculosis effect (P＜0.01) is arranged all, the height of medicine of the present invention wherein, middle dosage group (1.0g/kg.d 0.5g/kg.d) and positive control medicine isoniazid (0.03g/kg.d) group, isoniazid ten rifampicin (0.03g/kg.d ten 0.06g/kg.d) drug combination group is compared, the intravital tuberculosis effect of Cavia porcellus identical (P＞0.5) is better than Western medicine ethambutol (0.2g/kg.d) group (P＜0.05).Experimental result discloses the alternative isoniazid of medicine of the present invention in the Cavia porcellus body, or isoniazid ten rifampicin, is used for clinical treatment pharmacodynamics foundation lungy separately.
Concrete experimental data such as following table: (YLN in the table is the code name of medicine of the present invention)
Table 1 YLN is to the influence of Cavia porcellus body weight
| Group | With A dose (g/kg.d) | Number of animals (N) | The Cavia porcellus body weight (g, X ± S) |
| The blank control group YLN of Normal group model YLN YLN INH EMB INH+RFP drug combination group | - - 1.0 0.5 0.25 0.03 0.1 0.03+0.06 | 8 9 7 7 8 8 8 7 | 503.38±18.97 456.78±l7.73 *** 500.00±28.88 △△ 530.43±16.15 △△△ 523.50±14.87 △△△ 496.63±13.47 △△△▲▲ 503.38±10.18 △△△▲▲ 464.29±11.47 ▲▲▲ |
* *P＜0.001, model blank group and normal control group are relatively;
△ △P＜0.001,
△ △ △P＜0.001, medication group and mould
Type blank group relatively;
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.001, positive drug matched group and YLN0.5g/kg.d group are relatively.
Medicine of the present invention is to the influence (dissect dead animal, perusal GPS, lung, liver, injection site and lymph node tuberculosis degree are with the exponential formal representation of pathological changes) of Cavia porcellus pathological changes perusal pathogenic index
Table 2 Cavia porcellus pathological changes perusal pathogenic index
| Pathological changes | Diseased region | Injection site and lymph node | Pulmonary shadow, trachea, paratracheal lymph nodes |
| Spleen lung liver | |||
| The severe moderate is slight | 35 30 25 20 20 20 10 10 10 | 10 10 10 | 10 10 10 |
| Maximum | 35 30 25 | 10 | 10 |
Press observation, the evaluation rule of table 2, experimental result sees Table 3 tables 4
Table 3 YLN is to the influence of Cavia porcellus pathological changes perusal pathogenic index
| Group | Dosage (g/kg.d) | Number of animals (N) | The influence of Cavia porcellus pathological changes perusal pathogenic index (X ± SD) | |||
| Spleen | Lung | Liver | Injection site and lymph node | |||
| The blank control group YIN of Normal group model YLN YLN INH EMB INH+RFP | - - 1.0 0.5 0.25 0.03 0.1 0.03+0.06 | 8 10 8 8 8 8 8 8 | 0.00±0.00 28.50±9.14 * 8.75±3.54 △ 0.00±0.00 △ 11.25±8.35 △ 0.00±0.00 △ 5.00±5.35 △▲ 0.00±0.00 △ | 0.00±0.00 18±6.32 * 2.50±7.07 △△ 1.25±3.54 △ 7.50±7.07 △ 1.25±3.54 △ 6.25±5018 △ 0.00±0.00 △ | 0.00±0.00 22.50±2.64 * 6.25±5.18 △ 0.00±0.00 △ 1.25±3.54 △ 2.50±4.63 △ 1.25±3.54 △△ 1.25±3.54 △ | 0.00±0.00 10.00±0.00 ** 10.00±0.00 1.25±3.54 △△ 8.75±3.54 1.25±3.54 △△ 7.50±4.63 2.50±4.63 △ |
*P＜0.05,
*Compare with the normal control group P＜0.01; △ P＜0.05, △ △ P＜0.01, medication group and model blank
Matched group relatively; ▲ P＜0.05, the EMB group compares with YLN 0.5g/kg.d group.
Table 4 YLN is to the exponential influence of Cavia porcellus organ weights
| Group | Dosage (g/kg.d) | Number of animals (N) | Cavia porcellus organ weights index (X ± SD) | ||
| Spleen | Lung | Liver | |||
| The blank control group YLN of Normal group model YLN YLN INH EMB INH+RFP | - - 1.0 0.5 0.25 0.03 0.1 0.03+0.06 | 8 10 8 8 8 8 8 8 | 0.179±0.00947 0.229±0.0280 *** 0.175±0.0210 △△ 0.175±0.0259 △△ 0.239±0.0432 0.201±0.0411 0.186±0.0261 △△ 0.157±0.0375 △△ | 0.797±0.0224 1.168±0.110 *** 0.775±0.0686 △△ 0.805±0.0760 △△ 0.882±0.123 △△ 0.830±0.0400 △△ 0.908±0.0824 △△ 0.866±0.162 △△ | 4.211±0.145 5.483±0.460 *** 4.620±0.492 △△ 4.570±0.508 △△ 5.071±0.420 4.342±0.147 △△△ 4.427±0.368 △△ 4.751±0.464 △△ |
* *P＜0.001, model blank group and normal control group are relatively; △ △ P＜0.01, △ △ △ P＜0.001, medication group and model blank group are relatively.
As can be seen from Table 4, model blank group pathogenic index is significantly higher than normal control group (P＜0.001): the medication group, remove YLNO.25g/kg.d
-1Group spleen regulating liver-QI, the INH spleen causes a disease to count not to be had outside the influence, and all the other are respectively organized pathogenic index and obviously reduce (P＜0.01), near the normal control group.The middle and high dosage group of YLN curative effect is good with middle dosage group wherein near positive control medicine group.(0.098g/kg.d amounts to crude drug 22～30g/kg.d) equivalences to dosage group (0.5g/kg.d) with human clinical's dosage in the Cavia porcellus.
3, resist the experimental study of the mycobacterium tuberculosis strain of anti-the multiple medicines: the Cavia porcellus tuberculosis model of setting up the human-like mycobacterium tuberculosis bacterial strain of anti-the multiple medicines, with medicine of the present invention is experimental group, set up drug resistance knot disease model blank group simultaneously, the normal control group, treat the comparative study of many resistant tuberculosis, experimental result shows: dosage group (0.4g/kg) in this medicine, to clinical isolating and anti-multiple medicines (anti-isoniazid, streptomycin, rifampicin, different amine butanols) the tuberculosis guinea pig model of mycobacterium hominis's strain infection, have significant tuberculosis effect, learn by statistics and handle (P＜0.01).The effective pharmacodynamics foundation of this Drug therapy tuberculosis patient of anti-multiple medicines that Here it is.
4, the malicious conclusion (of pressure testing) of the urgency of medicine of the present invention is: the maximum tolerated dose MTD of its mouse oral is 40.00g/80ml/Kg, point out medicine its mouse oral LD50 of the present invention greater than the 40.00g/80ml/kg body weight, be calculated as 400 times of clinical application amount (the 0.1g/ body weight is amounted to crude drug 0.425g/kg body weight) by the 60kg body weight, LD50 does not obtain, and illustrates that clinical drug safety height, toxicity are minimum.
Of the present invention to therapeutical effect lungy for showing, clinical observation result is as follows:
1, accept consumptive's 100 examples for medical treatment, bone tuberculosis patient 60 examples are carried out the clinical observation of standardization, and the treatment conclusion is: the treatment effective percentage 97% of medicine of the present invention, cure rate 93%, inefficiency 3%.
2, accept the 40 routine tuberculosis patients of anti-the multiple medicines for medical treatment, medicine of the present invention is experimental group (30 example), western medicine group (10 example), and clinical observation result is: the treatment effective percentage 95% of this medicine, cure rate 89.5% is higher than the Western medicine chemotherapy group, and can shorten the course of treatment.
3, the observation of untoward reaction is observed through for many years clinic trial, does not find untoward reaction as yet, and the patient that takes medicine for a long time is normal through liver function, kidney merit, hemanalysis check result.Clinical drug safety is reliable, and continuous use is not found accumulation toxicity and drug resistance.
Another key character of the present invention is: this medicine has resist inflammation on repercussive function preferably, and to pneumonia, edema, as pneumonia, bronchitis, pleuritis also have better therapeutic effect.
Comprehensive drug, toxicology, clinical medical evaluation conclusion, medicine of the present invention has tangible produce effects.
The specific embodiment
Embodiment 1
Raw material: Caulis et Radix Periplocae Forrestii 500kg;
Production method: get Caulis et Radix Periplocae Forrestii 500kg, the decocting that adds 12 times of weight boils three times; Add for the first time the water of 6 times of weight, soaked 8 hours, boiled 2 hours, for the second time add 3 times of water yields, boiled 2 hours, add 3 times of water yields for the third time, boiled 1.5 hours, merging filtrate filters while hot, leaves standstill clarification 10 hours, get the supernatant mechanism filter-pressing, be further purified its active princlple by existing separating and purifying technology, purified medicinal liquid is concentrated into dilution thick paste (proportion 1.05-1.15, heat is surveyed 60 ℃), spray drying system fine silt, after adding the moistening fine silt of an amount of 95% ethanol, granulate, pick up and test, divide encapsulated, or add 3～10% adjuvants (dextrin etc.), and tabletting, packing is promptly.
Embodiment 2
Press routine proportioning and take by weighing raw material: Caulis et Radix Periplocae Forrestii 375kg, Radix Astragali 75kg, Radix Ophiopogonis 50kg.
Production method: with above-mentioned raw materials Caulis et Radix Periplocae Forrestii, the Radix Astragali, Radix Ophiopogonis, decoct with water three times, add for the first time the water of 6 times of weight, soak and boiled 2 hours after 8 hours, add 3 times of water yields for the second time and boiled 2 hours, adding 3 times of water yields for the third time boiled 1.5 hours, merge three times medicinal liquid, filter while hot, leave standstill clarification 8 hours, get the supernatant mechanism filter-pressing, filtrate be condensed into rare thick paste (proportion 1.05～1.35,60c), spray drying is made fine silt, after adding the moistening medicated powder of 95% ethanol, granulate check, capsule charge, packing, promptly.
Embodiment 3
Press routine proportioning and take by weighing raw material: Caulis et Radix Periplocae Forrestii 300kg, Radix Astragali 90kg, Radix Ophiopogonis 60kg, Bulbus Fritillariae Cirrhosae 50kg.
Production method: it is standby that the fine ground powder of above-mentioned raw materials Bulbus Fritillariae Cirrhosae is crossed 100 orders; With Caulis et Radix Periplocae Forrestii, the Radix Astragali, Radix Ophiopogonis, decoct with water three times, the water that adds for the first time 6～7 times of weight of three kinds of raw material total amounts, soak and boiled 2 hours after 5～8 hours, for the second time add 3～4 times of water yields of three kinds of raw material total amounts and boiled 1.5～2 hours, add 3～4 times of water yields of three kinds of raw material total amounts for the third time and boiled merging filtrate 1.5～2 hours, filtered while hot, leave standstill clarification 8～10 hours, get the supernatant mechanism filter-pressing, filtrate is concentrated into thick paste (proportion 1.05～1.10, heat is surveyed 60 ℃), spray drying is made powder, adds the Bulbus Fritillariae Cirrhosae fine powder, after stirring, add 1～2 times of amount of total powder weight, 95% ethanol, make the moistening appropriateness of medicated powder, pelletizing press sheet or granulate encapsulated, the packing promptly.
Claims (8)
1, a kind of treatment tuberculosis, it is characterized in that it is is the medicament that raw material is made by the following method with the Caulis et Radix Periplocae Forrestii: with 50～75% soak with ethanol of 3～6 times of Caulis et Radix Periplocae Forrestii gross weights after 3～7 days, filter is pure liquid to the greatest extent, reclaim ethanol, medicinal residues decoct with water three times, 5～8 times of water gagings boiled 2～3 hours for the first time, for the second time, respectively add 3～4 times of water gagings for the third time, boiled 1～2 hour, merge three times filtrate, filter while hot, leave standstill clarification 8～10 hours, the supernatant filter press, it is condensed into rare thick paste filtrate and above-mentioned medicinal liquid, be spray dried to powder, granulate, divides encapsulated or compacting in blocks.
2, a kind of treatment tuberculosis is characterized in that it is is main material with the Caulis et Radix Periplocae Forrestii, the medicament of making by following weight percent proportion raw material:
1%～20% Radix Ophiopogonis 0～20% of Caulis et Radix Periplocae Forrestii 60%～99% Radix Astragali.
3, according to the described treatment tuberculosis of claim 2, it is characterized in that the per distribution ratio of each raw material is:
5%～15% Radix Ophiopogonis 5～15% of Caulis et Radix Periplocae Forrestii 70%～90% Radix Astragali.
4,, it is characterized in that also adding Bulbus Fritillariae Uninbracteatae cough-relieving tonifying the lung medicine according to the described treatment tuberculosis of claim 3.
5,, it is characterized in that the Caulis et Radix Periplocae Forrestii raw material replaces with spending more blue or green mabi in the P. sepium Bunge genus according to claim 1 or 2 or 3 or 4 described treatment tuberculosis.
6, according to claim 1 or 2 or 3 or 4 described treatment tuberculosis, it is characterized in that said medicine is used for the treatment of the diseases associated with inflammation of tuberculosis and pulmonary.
7, by the preparation method of the described treatment tuberculosis of claim 2, it is characterized in that getting Caulis et Radix Periplocae Forrestii, the Radix Astragali decocts with water three times, 6～7 times of water gagings soak after 6～8 hours and boiled 2～3 hours for the first time, respectively add 3～4 times of water gagings for the second time, for the third time, respectively boiled 1.5～2 hours, merge three times filtrate, filter while hot, leave standstill clarification, get the supernatant filter press, filtrate concentrates, be spray dried to powder, with adjuvants such as amylodextrins, mixing, granulate, divide encapsulated or be pressed into tablet.
8, press the preparation method of claim 3 or 4 described treatment tuberculosis, it is characterized in that getting Caulis et Radix Periplocae Forrestii, the Radix Astragali, Radix Ophiopogonis decocts with water three times, 6～7 times of water gagings soak after 6～8 hours and boiled 2～3 hours for the first time, for the second time, respectively add 3～4 times of water gagings for the third time, respectively boiled 1.5～2 hours, merge three times filtrate, filter while hot, leave standstill clarification, get the supernatant filter press, filtrate concentrates, be spray dried to powder, with adjuvants such as amylodextrins, mixing, granulate, divide encapsulated or neutralize into tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117534 CN1251696C (en) | 2003-03-24 | 2003-03-24 | Medicine for treating tuberdulosis and lung disease and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117534 CN1251696C (en) | 2003-03-24 | 2003-03-24 | Medicine for treating tuberdulosis and lung disease and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1531957A CN1531957A (en) | 2004-09-29 |
| CN1251696C true CN1251696C (en) | 2006-04-19 |
Family
ID=34284763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117534 Expired - Lifetime CN1251696C (en) | 2003-03-24 | 2003-03-24 | Medicine for treating tuberdulosis and lung disease and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1251696C (en) |
-
2003
- 2003-03-24 CN CN 03117534 patent/CN1251696C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1531957A (en) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN102441071B (en) | Healthcare oral liquid | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN1251696C (en) | Medicine for treating tuberdulosis and lung disease and its preparing method | |
| CN107854565B (en) | Anti-radiation traditional Chinese medicine composition | |
| CN103330781A (en) | Traditional Chinese medicine composite with anti-tumor effect and preparation method of injection of same | |
| CN1114443C (en) | Medicine for induction-differential therapy and its application | |
| CN102078600A (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN1053363C (en) | Oral liquid of shengxueyin | |
| CN103768454B (en) | A kind of composition with prevention and treatment HIV/AIDS and preparation method thereof | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN1723956A (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN114588195B (en) | Preparation and application of compound traditional Chinese medicine composition for regulating tumor immunity and resisting tumor | |
| CN107802681B (en) | Composition for improving clinical symptom sign of HIV infected person | |
| CN102416087A (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method as well as application thereof | |
| CN1116069C (en) | Health care oral liquid for old people and preparation process thereof | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process | |
| CN1981807A (en) | Medicinal composition for preventing and treating hepatitis and hepatocarcinoma and its production | |
| CN1091382C (en) | Compound Lingxian headache-treating capsule and its preparation | |
| CN1080563C (en) | Series medicinal preparation for treating cancer and production method thereof | |
| CN1114420C (en) | Medicine for treating intractable ischias and chronic lumbocrural pain and its preparing process | |
| CN1879778A (en) | Headache-treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060419 |